Spots Global Cancer Trial Database for high risk
Every month we try and update this database with for high risk cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma | NCT02043860 | Multiple Myelom... | Total Marrow Ir... Autologous Tran... Melphalan Filgrastim (G-C... | 18 Years - 75 Years | University of Illinois at Chicago | |
| Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study | NCT05149248 | Cancer of Cervi... | Gardasil® [Quad... Two dose Control group 2 dose vaccinat... | 14 Years - 45 Years | Instituto Nacional de Salud Publica, Mexico | |
| Efficacy of Postoperative Adjuvant Chemotherapy for Stage II Colon Cancer With High Risk Factors(EPAC1) | NCT03199989 | Adjuvant Chemot... | CapeOX（Capecita... Observation | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi) | NCT06229041 | Rectal Cancer | Camrelizumab ＋I... | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects in DNA Repair Genes | NCT03432897 | Prostate Cancer Adenocarcinoma ... | Olaparib Pill Prostatectomy | 18 Years - | Brown University | |
| Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer | NCT02446444 | Prostatic Neopl... | Enzalutamide Conventional NS... LHRHA External Beam R... | 18 Years - | University of Sydney | |
| A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) | NCT04196491 | Multiple Myelom... | bb2121 Fludarabine Cyclophosphamid... Lenalidomide | 18 Years - | Celgene | |
| Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC | NCT04565054 | Breast Cancer F... | Abemaciclib 50 ... | 18 Years - | West German Study Group | |
| Efficacy of Postoperative Adjuvant Chemotherapy for Stage II Colon Cancer With High Risk Factors(EPAC1) | NCT03199989 | Adjuvant Chemot... | CapeOX（Capecita... Observation | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA | NCT01531205 | Prostate Cancer | Androgen Ablati... Cabazitaxel Salvage Therapy Neoadjuvant Tre... Neoadjuvant Tre... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer | NCT05704829 | HER2-positive E... | Trastuzumab der... Standard-of-Car... | 18 Years - | West German Study Group | |
| Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer | NCT00242918 | Prostate Cancer | docetaxel ZD1839 | 18 Years - | Benaroya Research Institute | |
| Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer | NCT02064608 | Prostate Cancer | AZD2014 | 18 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| Boost Irradiation to the Supraclavicular Area Among High Risk cN3c Breast Cancer Patients | NCT06404697 | Breast Cancer | Boost irradiati... | 18 Years - | Ruijin Hospital | |
| Breast Stem Cells in Women at Average Risk and Increased Risk for Breast Cancer | NCT00923377 | Breast Cancer | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA | NCT01531205 | Prostate Cancer | Androgen Ablati... Cabazitaxel Salvage Therapy Neoadjuvant Tre... Neoadjuvant Tre... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04) | NCT01502982 | Diffuse Large B... | R-CHOEP14x6+HD-... | 18 Years - 64 Years | Nordic Lymphoma Group | |
| Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes | NCT01700049 | Basal Cell Carc... | vismodegib (150... | 18 Years - | Mayo Clinic | |
| NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer | NCT05704829 | HER2-positive E... | Trastuzumab der... Standard-of-Car... | 18 Years - | West German Study Group | |
| Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer | NCT02777385 | Head and Neck S... | Pembrolizumab Cisplatin IMRT | 18 Years - | University of Pittsburgh | |
| Susceptibility to Breast Cancer | NCT00004565 | Breast Cancer Healthy | - | National Institutes of Health Clinical Center (CC) | ||
| Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes | NCT01700049 | Basal Cell Carc... | vismodegib (150... | 18 Years - | Mayo Clinic | |
| Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi) | NCT06229041 | Rectal Cancer | Camrelizumab ＋I... | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Pilot Study of High Risk Lung Cancer Screening | NCT03683940 | Lung Cancer | Screening | 40 Years - 82 Years | University of Colorado, Denver | |
| Sonographic Visibility of Breast Biopsy Marker Clips Up to 4 Weeks After Placement | NCT00548392 | Breast Cancer | 18 Years - | Fred Hutchinson Cancer Center | ||
| Susceptibility to Breast Cancer | NCT00004565 | Breast Cancer Healthy | - | National Institutes of Health Clinical Center (CC) | ||
| Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer | NCT05658172 | Breast Cancer | Determination o... Determination o... Determination o... Biobanking of b... | 18 Years - 75 Years | University of Ulm | |
| Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study) | NCT05778097 | Prostate Cancer Biochemical Rec... High Risk | Apalutamide 60m... Androgen depriv... | 18 Years - 75 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| Development of Early Detection Signs for Gastrointestinal Cancer | NCT00633334 | GI Cancer | Specimen bank | 18 Years - | University of Pittsburgh | |
| A First Step Towards Ultra-hypofractionation for Unfavourable Intermediate and High-risk Prostate Cancer | NCT05361902 | Prostate Cancer | Adaptive radiot... | 18 Years - | Erasmus Medical Center | |
| VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma | NCT03641456 | Myeloma Newly Diagnosed High Risk | bortezomib Lenalidomide Dexamethasone | 18 Years - 75 Years | Sun Yat-sen University | |
| Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer | NCT00699907 | Ovarian Cancer | flutamide | 18 Years - 83 Years | University of Arizona | |
| Cancer Screening and Prevention Program for High Risk Women | NCT00849199 | Ovarian Cancer Breast Cancer | 18 Years - | NYU Langone Health | ||
| Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma | NCT03969004 | Cutaneous Squam... | Cemiplimab Placebo | 18 Years - | Regeneron Pharmaceuticals | |
| Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer | NCT02446444 | Prostatic Neopl... | Enzalutamide Conventional NS... LHRHA External Beam R... | 18 Years - | University of Sydney | |
| Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer | NCT01244789 | Endometrial Can... | carboplatin and... observation | 18 Years - | Danish Gynecological Cancer Group | |
| Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection | NCT06409702 | Newly Diagnosed High Risk MRD Multiple Myelom... | Carfilzomib Daratumumab Lenalidomide Dexamethasone VRD for first-c... | 18 Years - | The First Affiliated Hospital of Soochow University | |
| Protons vs. Photons for High-risk Prostate Cancer | NCT05350475 | Prostate Cancer Radiotherapy Si... | Proton therapy Photon therapy | 18 Years - | University of Aarhus | |
| Improve Colorectal Cancer Prevention by Motivational and Community-based Approaches | NCT05568667 | Colorectal Canc... | Low risk Moderate risk High risk | 18 Years - 80 Years | Centre Leon Berard | |
| A Safety and Efficacy of CCRT With Paclitaxel as Adjuvant Therapy to Post-Operative Advanced Endometrial Cancer Patients | NCT00373620 | Endometrial Can... | paclitaxel | 20 Years - 75 Years | Korean Gynecologic Oncology Group | |
| Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML) | NCT01422603 | Acute Myeloid L... Myelodysplasia | Clofarabine Clofarabine | 18 Years - | University Hospital Southampton NHS Foundation Trust | |
| Peripheral Blood Stem Cell Transplant (PBSCT) in Children With High Risk or Recurrent Solid Tumors | NCT00966498 | High Risk Solid... Recurrent Solid... | Peripheral Bloo... | - 35 Years | Emory University | |
| Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients | NCT02973386 | Local Advanced ... | IMRT combine wi... IMRT combine wi... | 18 Years - 70 Years | Sun Yat-sen University | |
| What Are the Benefits and Harms of Risk Stratified Screening in the NHS Breast Screening Programme: Study Protocol | NCT04359420 | Breast Cancer | BC-Predict NHS Breast Scre... | - | University of Manchester | |
| Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer | NCT01244789 | Endometrial Can... | carboplatin and... observation | 18 Years - | Danish Gynecological Cancer Group | |
| The Role of the Novel 99mTc-NC100692 Tracer in Patients at High Risk or Known Breast Cancer | NCT01503697 | Breast Cancer Tumor Angiogene... | 18 Years - | Tel-Aviv Sourasky Medical Center | ||
| An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients | NCT03606577 | Multiple Myelom... | Carfilzomib Daratumumab Lenalidomide Dexamethasone | 18 Years - 65 Years | Nantes University Hospital | |
| Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia | NCT00497809 | Breast Cancer Neutropenia | AVI-014 versus ... | 18 Years - | AviGenics | |
| A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients Without Metastasis | NCT03258320 | Prostate Cancer... | Cabazitaxel, Do... | 40 Years - 75 Years | Shanghai Jiao Tong University School of Medicine | |
| Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer | NCT04737109 | Castrate Resist... | Ipatasertib Darolutamide Androgen Depriv... | 18 Years - | Big Ten Cancer Research Consortium | |
| ELDA: Elderly Breast Cancer - Docetaxel in Adjuvant Treatment | NCT00331097 | Breast Cancer | docetaxel cyclophosphamid... methotrexate 5-fluorouracil | 65 Years - 80 Years | National Cancer Institute, Naples | |
| Observation of Outcomes and Side Effects of Cesium-131 in Combination With External Beam Radiation for the Treatment of Intermediate to High Risk Prostate Cancer | NCT00621413 | Prostate Cancer | 18 Years - | IsoRay Medical, Inc. | ||
| Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML) | NCT01422603 | Acute Myeloid L... Myelodysplasia | Clofarabine Clofarabine | 18 Years - | University Hospital Southampton NHS Foundation Trust | |
| Pilot Study of High Risk Lung Cancer Screening | NCT03683940 | Lung Cancer | Screening | 40 Years - 82 Years | University of Colorado, Denver | |
| Kidney Cancer DNA Registry | NCT02087852 | Renal Cancer | salvia for germ... the Kidney Canc... Family History ... Blood draw Epidemiologic Q... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer | NCT00828308 | Prostate Cancer | Ixabepilone Prostatectomy | 18 Years - | Brown University | |
| NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer | NCT05704829 | HER2-positive E... | Trastuzumab der... Standard-of-Car... | 18 Years - | West German Study Group | |
| Safety Study of Pelvic and Prostatic SIB-IMRT With Long-term Androgen Deprivation for High Risk Localized Prostate Cancer | NCT01704027 | Prostate Cancer | Simultaneous in... Androgen depriv... | 18 Years - 85 Years | Centre Georges Francois Leclerc | |
| Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma | NCT03969004 | Cutaneous Squam... | Cemiplimab Placebo | 18 Years - | Regeneron Pharmaceuticals | |
| Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer | NCT00828308 | Prostate Cancer | Ixabepilone Prostatectomy | 18 Years - | Brown University | |
| Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer | NCT01481545 | Rectal Cancer | Radiation thera... Oxaliplatin Raltitrexed levofolinic aci... 5-fluorouracil Bevacizumab | 18 Years - | National Cancer Institute, Naples | |
| Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Randomized Control Clinical Trial | NCT02143388 | Local Advanced ... | IMRT combine wi... IMRT combine wi... | 18 Years - 70 Years | Sun Yat-sen University | |
| Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma | NCT03969004 | Cutaneous Squam... | Cemiplimab Placebo | 18 Years - | Regeneron Pharmaceuticals | |
| Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma | NCT05422027 | Multiple Myelom... | Selinexor Bortezomib Lenalidomide Dexamethasone | 18 Years - | Sun Yat-sen University | |
| External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer | NCT01603420 | Prostate Cancer | Luteinizing hor... Docetaxel Conformal Radia... | 18 Years - 75 Years | Proton Collaborative Group | |
| Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis | NCT03293173 | Lymphoma, Large... | R-CHOEP DA-EPOCH-R | 18 Years - 64 Years | Nordic Lymphoma Group | |
| Improve Colorectal Cancer Prevention by Motivational and Community-based Approaches | NCT05568667 | Colorectal Canc... | Low risk Moderate risk High risk | 18 Years - 80 Years | Centre Leon Berard | |
| Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer | NCT00544167 | Breast Cancer | Doxorubicin Cyclophosphamid... Paclitaxel Sorafenib | 18 Years - | SCRI Development Innovations, LLC | |
| Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients | NCT00929019 | Uveal Melanoma | autologous dend... | 18 Years - 75 Years | Radboud University Medical Center | |
| TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature | NCT02641847 | Triple Negative... Breast Cancer | docetaxel doxorubicin or ... cyclophosphamid... gemcitabine cisplatin | 18 Years - 70 Years | Fudan University | |
| Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia | NCT01990807 | Childhood Acute... Philadelphia Ch... B-cell Childhoo... | Idarubicin(IDA) | 6 Months - 18 Years | ChineseAMS | |
| Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer | NCT02064608 | Prostate Cancer | AZD2014 | 18 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| Cryotherapy With or Without Short-term Adjuvant Androgen-Deprivation Therapy in Prostate Cancer | NCT01398657 | Prostate Cancer | Adjuvant Androg... | 20 Years - | National Taiwan University Hospital | |
| RPFNA Assessment of Exercise Effect in Breast Cancer | NCT01961128 | Breast Cancer | Exercise Interv... | 18 Years - 50 Years | Dana-Farber Cancer Institute | |
| A Safety and Efficacy of CCRT With Paclitaxel as Adjuvant Therapy to Post-Operative Advanced Endometrial Cancer Patients | NCT00373620 | Endometrial Can... | paclitaxel | 20 Years - 75 Years | Korean Gynecologic Oncology Group | |
| Identification of High Risk People for Colorectal Cancer and Evaluation of a Specific Surveillance System | NCT02931825 | Cancer Colorect... | Reminder letter | 50 Years - 74 Years | University Hospital, Tours | |
| iCAT for Recurrent/Refractory/HR Solid Tumors | NCT01853345 | Pediatric Solid... Sarcoma Neuroblastoma Wilms Tumor | - 30 Years | Dana-Farber Cancer Institute | ||
| Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394) | NCT00590785 | High Risk Breast Cancer Positive Nodes Cyclophosphamid... Doxorubicin | Doxorubicin Cyclophosphamid... G-CSF tamoxifen ciprofloxacin | - | National Cancer Institute (NCI) | |
| A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients | NCT01788137 | T-cell Lymphoma... Previously Untr... High Risk | chemotherapy (C... chemotherapy(c-... | 18 Years - 70 Years | Sun Yat-sen University | |
| A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer | NCT04543695 | Rectal Cancer | Concurrent Chem... XELOX mFOLFOX TME | 18 Years - 75 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
